Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Wednesday
by Scott Moore · The Cerbat GemAnika Therapeutics (NASDAQ:ANIK – Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $28.1420 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:30 AM ET.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last announced its earnings results on Thursday, February 26th. The biotechnology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.29. Anika Therapeutics had a negative return on equity of 6.26% and a negative net margin of 9.64%.The company had revenue of $30.62 million for the quarter, compared to analysts’ expectations of $28.88 million. On average, analysts expect Anika Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Anika Therapeutics Trading Down 1.9%
Anika Therapeutics stock traded down $0.30 during trading on Tuesday, reaching $15.55. The company had a trading volume of 34,441 shares, compared to its average volume of 137,572. Anika Therapeutics has a 52 week low of $7.87 and a 52 week high of $16.24. The firm’s 50-day simple moving average is $14.14 and its 200 day simple moving average is $11.23. The firm has a market capitalization of $208.44 million, a price-to-earnings ratio of -20.45 and a beta of 0.28.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anika Therapeutics in a report on Monday, December 29th. Barrington Research upped their price target on shares of Anika Therapeutics from $16.00 to $17.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Finally, Wall Street Zen upgraded shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $17.00.
Read Our Latest Stock Analysis on ANIK
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Corient Private Wealth LLC lifted its holdings in shares of Anika Therapeutics by 4.3% in the 4th quarter. Corient Private Wealth LLC now owns 32,224 shares of the biotechnology company’s stock valued at $310,000 after acquiring an additional 1,324 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Anika Therapeutics by 7.9% in the 4th quarter. Invesco Ltd. now owns 25,272 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 1,843 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Anika Therapeutics during the 4th quarter valued at approximately $122,000. NewEdge Advisors LLC bought a new position in shares of Anika Therapeutics during the 4th quarter valued at approximately $139,000. Finally, XTX Topco Ltd increased its position in shares of Anika Therapeutics by 74.3% during the 4th quarter. XTX Topco Ltd now owns 22,252 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 9,482 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.
About Anika Therapeutics
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.